PATENT CLAIM ANALYSIS

Application Number: 16184748
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["435", "006100"]

Abstract:
A gene expression signature identifies stage II colon and/or Stage III cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.

Claim (Index 1):
A method of treating a colon cancer patient comprising:\n a) obtaining a colon cancer tumor tissue sample from a patient with colon cancer, b) contacting a genetic sample from said colon cancer tumor tissue sample with a plurality of specific genetic sequence binding targets and measuring the expression level of a panel consisting essentially of 72 genes, wherein the 72 genes are AKAP12, ANKRD44, BGN, BHLHE41, BMP7, C8orf84, CAB39L, CDKN2B, CKMT2, COL11A1, COMP, CPE, CSGALNACT1, CXCL10, CXCL11, CXCL13, CXCL2, CXCL9, CYP1B1, DAPK1, DCBLD2, DPEP1, EPB41L4B, ERAP2, F5, FAP, FGL2, FN1, FNDC1, GBP1, GBP4, GPX3, GRM8, GZMB, HGD, HOXA13, HSD17B2, ID4, IDO1, IL8, INHBA, MFAP5, MGP, MMP11, MMP28, NFIB, OAS2, PAPPA, PIGR, PLA2G12B, POU2AF1, PRAP1, PROM2, PSMB9, PTPRC, ROBO1, SDC2, SELL, SERPINE1, SFRP2, SGK2, SLC4A4, SPARC, SPP1, SSPN, STC1, TACSTD2, TGFBR3, TM4SF1, TYMS, VCAN, and VNN1, c) obtaining a gene expression signature for said colon cancer tumor tissue from the gene expression level of the panel of 72 genes in b), d) responsive to the gene expression signature, identifying said colon cancer tumor tissue as being a subtype responsive to oxaliplatin.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 98.0
- Lexical Diversity: 1.33824
- Patent Class: 435.0
- Transitional Phrase Type: half
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14738757', '14346693', '14209266', '13992020', '13401780']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5389137679742692
- 35 USC 102 Novelty (BERT): 0.6781440517734622
- Combined Prediction Score: 0.5528367963541885
- Mean Citation Score: 303.936754
- Max Citation Score: 671.14923
- Similarity Product: 650.0194824489713

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test